Flagship takes on a pioneering new fund — and name — adding $285M to advance its startup mission
Flagship has become one of the most prominent blank-slate venture funds in biotech, creating companies from scratch in search of engineering major change in the way disease is treated. And it will begin 2017 with a new fund to invest in the continued growth of the companies it sparks into existence, along with a new name the Cambridge the MA-based group hopes will better reflect its mission.
It starts with a $285 million Special Opportunities Fund which will now operate alongside its $585 million Fund V, unveiled 21 months ago. And the venture group will be known as Flagship Pioneering as it starts its 17th year in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.